Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Accumulated Depreciation (2016 - 2025)

Seres Therapeutics' Accumulated Depreciation history spans 11 years, with the latest figure at $56.4 million for Q3 2025.

  • For Q3 2025, Accumulated Depreciation changed N/A year-over-year to $56.4 million; the TTM value through Sep 2025 reached $56.4 million, changed N/A, while the annual FY2023 figure was $49.1 million, 8.97% up from the prior year.
  • Accumulated Depreciation for Q3 2025 was $56.4 million at Seres Therapeutics, up from $55.3 million in the prior quarter.
  • Across five years, Accumulated Depreciation topped out at $56.4 million in Q3 2025 and bottomed at $35.8 million in Q1 2021.
  • The 5-year median for Accumulated Depreciation is $46.4 million (2023), against an average of $46.9 million.
  • The largest annual shift saw Accumulated Depreciation rose 18.0% in 2021 before it grew 2.82% in 2025.
  • A 5-year view of Accumulated Depreciation shows it stood at $40.3 million in 2021, then rose by 11.85% to $45.0 million in 2022, then rose by 8.97% to $49.1 million in 2023, then rose by 9.65% to $53.8 million in 2024, then increased by 4.76% to $56.4 million in 2025.
  • Per Business Quant, the three most recent readings for MCRB's Accumulated Depreciation are $56.4 million (Q3 2025), $55.3 million (Q2 2025), and $54.3 million (Q1 2025).